Programs
- Seminar Series
- HIV Education & Training
- Active Studies
Active HIV Research Studies
About this Page
This page hosts a collection of HIV and HIV-related research at the University of California San Diego and affiliated sites. Progress in treatment for HIV, hepatitis C, hepatitis B, tuberculosis, and other related conditions only occurs with the valuable contributions of individuals who enroll in research studies. These clinical research trials help improve the treatment and management of HIV and other infections.
We encourage you to bookmark this page and check back often, as new opportunities to participate in HIV and related research are added frequently.
This page is managed by The HIV Institute at the University of California San Diego. Contact us at hiv@ucsd.edu with any questions, feedback, or recommendations. Please note, inquiries regarding a specific study or sponsoring center should be directed to the contact listed. The HIV Institute does not manage any of these studies.
To see all HIV/AIDS clinical trials at UC San Diego (including those in progress as well as actively enrolling studies), please visit the UC San Diego Health Clinical Trials page.
If you are interested in including a research opportunity on this page, please click the button below to submit details.
*Disclaimer: Each sponsoring center and/or principal investigator is responsible for the studies listed on this website. This includes study preparation, conduct, and administration of a research grant, cooperative agreement, training or public service project, contract, or other sponsored project in compliance with applicable laws and regulations and institutional policy governing the conduct of sponsored research. Contact the indicated party listed below with any study-related questions.
Antiviral Research Center (AVRC)
To enroll in or get more information about one of these clinical trials at the AVRC, please call the Screening Coordinator at (619) 543-3740 or email Marvin Hanashiro at mhanashiro@health.ucsd.edu
Click here to see a full list of the Antiviral Research Center's currently enrolling studies.
SCORPIO-HR/ACTIV-2D
Several treatments are now being used for COVID-19. However, new treatment options are needed to help people recover faster from COVID-19. The SCORPIO-HR study is a clinical research study looking at whether an investigational drug for COVID-19 can help resolve COVID-19 symptoms faster in people who have tested positive.
Click here for more information and eligibility requirements.
COVID-19
ACTG A5321 (AHRC)
Studying differences and changes over time in HIV reservoirs (groups of HIV-infected cells that 'hide' from anti-HIV medications) and attempting to answer questions about the ways that HIV infection is controlled. This may have to do with a person’s viral load and CD4 count, when they started their anti-HIV medications, and genetic factors.
Click here for more information and eligibility requirements.
HIV
ACTG A5355
The purpose of this study is to see if an investigational vaccine for CMV (called Triplex®) is safe when given to people with both HIV and CMV. This study will also collect information on the effectiveness of Triplex® to reduce inflammation and immune activation markers compared to a placebo. This will be the first time that this type of information will be collected.
Click here for more information and eligibility requirements.
HIV
ACTG A5359 (LATITUDE)
This study is investigating if Long-Acting (LA) Injectable ART will be more successful for people who are non-adherent to their HIV medications than oral standard of care regimens. The main advantages of LA ART in this population include infrequent dosing and directly observed therapy. A challenge for participants is that to be eligible to receive LA ART, they will need to attain virologic suppression through adherence to their SOC oral medications.
Click here for more information and eligibility requirements.
HIV
ACTG 5383
The purpose of this study is to learn whether people living with well-controlled HIV and symptom-free cytomegalovirus (CMV) can reduce inflammation by taking a drug approved by the FDA (called letermovir) to prevent CMV disease.
Click here for more information and eligibility requirements.
HIV
ACTG 5386 (N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART)
Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment (ART) is unable to reach. IL-15 superagonist (N-803) appears to reactivate HIV that is "asleep" and is also thought to increase the body's natural immune response to HIV. Broadly neutralizing antibodies (bNAbs), such as 10-1074 and VRC07-523LS, have been shown to control growth of HIV in the blood and to increase the body's immune response to HIV. N-803 alone or in combination with bNAbs may provide greater control of HIV than previous efforts.
Click here for more information and eligibility requirements.
HIV
ACTG 5391 (Do IT)
This research study is trying to find out if people living with HIV who had > 10% weight gain after starting an antiretroviral therapy (ART) regimen that included an INSTI in combination with TAF/FTC (or TAF/3TC) could gain less weight, or maybe lose weight, after switching to an ART regimen containing doravirine (DOR) with either TAF/FTC (or TAF/3TC), or the related medication tenofovir disoproxil fumarate/emtricitabine (TDF/FTC [or TDF/3TC]). DOR is an FDA-approved antiretroviral drug for the treatment of HIV-1 and a member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) medication class. In multiple studies, DOR was shown to be just as effective as INSTI medications for treating HIV.
Click here for more information and eligibility requirements.
HIV
ACTG 5415
This research study is to learn more about the effects of Cenicriviroc (CVC) on inflammation and heart health in people living with HIV. We want to learn if CVC can lower vascular inflammation by looking at the aorta (the main artery in your body) through a test named FDG PET- CT. This test will be done before starting study drug and at study week 24.
Click here for more information and eligibility requirements. HIV
LAST GIFT
People at the end of their lives often have a unique perspective on life, death and altruism, and may hold the keys to curing HIV. This study takes the next steps in finding a cure for HIV by understanding how reservoirs are distributed throughout the body.
Click here for more information and eligibility requirements.
HIV
A5418 (STOMP)
Tecovirimat (also known as TPOXX) is a drug that may help to treat infections caused by pox viruses. Tecovirimat is approved by the Food and Drug Administration (FDA) to treat smallpox in adults and children. Its use in this study is considered investigational. An investigational use is one that has not been approved by the FDA. Tecovirimat has been approved for use in this study based only on data from animals. We don’t know for sure if it works to treat any infections in people. The FDA has reviewed information on tecovirimat and determined that tecovirimat may help treat infection, including serious or potentially life-threatening disease from poxviruses.
Click here for more information and eligibility requirements.
MPOX
PURPOSE-2 (Injectable PrEP Study)
An investigational twice-a-year injection medication can help reduce the risk of getting HIV from sex. Compensation for study-related time and travel will be provided to all participants. Participants can continue taking gender-affirming hormones during this study if need be.
Click here for more information and eligibility requirements.
HIV SEXUAL HEALTH
HIV Neurobehavioral Research Program (HNRP)
To enroll in or get more information about research studies at the HNRP, please call (619) 543-5000 and ask to speak with a research recruiter.
You may be eligible to participate if you:
•are at least 18 years old
•are HIV+ or HIV- (do not have HIV)
•do or do not have a history of substance use
For participating you will receive:
•Monetary compensation
•Lab results (at no cost to you)
•Medical and psychological test results (upon request at no cost to you)
*All information obtained during the study is kept strictly confidential.
iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV
Summary: HIV is associated with a pattern of neurocognitive deficits, metabolic dysfunction, and an elevated risk for cardiovascular disease (CVD), phenomena that remain untreated despite the use of medications to control the disease. This proposal will examine the effect of a personalized, automated, interactive mobile phone text message intervention (iSTEP) designed to increase moderate physical activity (PA), decrease sedentary behavior (SB), and promote a healthy Mediterranean-style diet (MedDiet) in persons living with HIV (PLWH). The investigators propose that participants who receive the iSTEP intervention will increase the amount of physical activity, improve their diet, show a reduction in risk factors for CVD, and exhibit improved neurocognitive performance.
Click here for more information and eligibility requirements
HIV
DETECT: A novel device to assess how HIV affects neurocognitive decline and postural instability in older adults at risk for Alzheimer's Disease
This is a research study to determine if a brief virtual reality (VR) assessment among older adults living with HIV can help us better screen for changes in cognition and balance.
Click here to download information on this study
Email: hnrprecruitment@ucsd.edu for more information or if you are interested in enrolling
HIV
Biomarkers of Resilience and injury related to HIV and Methamphetamine (BRIHM)
This project will look at METH and HIV-associated biomarker signatures of CNS injury and resilience and will translate them to the clinical environment.
Click here to download information on this study
Email hnrprecruitment@ucsd.edu for more information or if you are interested in enrolling
HIV
Cross-species studies of smoking effects on cognition and neuroinflammation in HIV
This study will examine how smoking affects people living with HIV, specifically the function and performance of the brain.
Click here to download information on this study
Email: hnrprecruitment@ucsd.edu for more information or if you are interested in enrolling
HIV
Mother Child Adolescent Program (MCAP)
To enroll or get more information about one of these IMPACT studies at MCAP, please email Study Coordinator: Alejandra Leon at a5leon@health.ucsd.edu
IMPAACT 2015: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission
The study will explore the effects of early intensive antiretroviral therapy (ART) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among HIV-infected infants.
Click here for more information and eligibility requirements.
HIV INFANTS
This study will evaluate the pharmacokinetic (PK) properties of antiretroviral (ARV) and anti-tuberculosis (TB) drugs administered during pregnancy and postpartum.
Click here for more information and eligibility requirements.
HIV PREGNANCY
The purpose of this study is to determine the dosage for oral and IM Cabotegravir LA and IM Rilpiverine LA and evaluate the safety, acceptability, tolerability, and pharmacokinetics of oral and long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed HIV-infected children and adolescents.
Click here for more information and eligibility requirements.
HIV CHILDREN 12-17
Owen Clinic
Check back soon for clinical trial updates for Owen Clinic.
Other UC San Diego HIV Research Studies
LOTUS Study
The LOTUS Study is recruiting women to share their thoughts on accessing sexual health services and mobile technology use so they can develop a mobile app. View the enrollment flyer.
Enrollment Now
SEXUAL HEALTH
Women SHINE is a research study aimed at helping women living with HIV to access and stay engaged in HIV care. Women SHINE is currently enrolling women living with HIV who have experienced violence during their adult life. View enrollment flyer
Enrollment: Now
HIV
MACH2: Measuring Brain Effects of Adversity, Cannabis and HIV - Phase 2
The goal of the MACH2 study is to find out how HIV, cannabis use and adversity affect the brain among young adults. We are seeking people age 18-24 with or without HIV and with all levels of cannabis use, from none to daily, but not current use of methamphetamine, cocaine or opioids. Participation involves cognitive testing, questionnaires and interviews, brain imaging, and a blood draw. You will be compensated up to $250. For information or to be screened for the study, contact Kathy Scarvie (see below).
Enrollment: Now through March 2024
Contact: Kathy Scarvie via email at kscarvie@health.ucsd.edu or call/text 858-951-7384
HIV CANNABIS
If you are 18 years or older and identify as a Latino man who has sex with other men, you may be eligible for the NEXUS study! Participants in this study will participate in a baseline survey and two additional follow-ups at 6 and 12 months' time. Participants can receive up to $360 for full study completion.
Enrollment: Now through December 2023
Contact: Jordan Silva; Email: jsilva@health.ucsd.edu
Click here for more information and eligibility requirements.
SEXUAL HEALTH
Summary: The goal of this study is to assess feasibility and acceptability and determine preliminary effects of Linkpositively, a culturally-tailored and trauma-informed smartphone app, on HIV care outcomes (i.e., retention in care, ART adherence, viral suppression) and mechanism of change variables (i.e., social support, self-efficacy). Participants will be randomly assigned to either the intervention (LinkPositively smartphone app, n=40) or control (Ryan White standard of care, n=40) arm, with follow-up at 3- and 6- months. Participants assigned to LinkPositively will complete 5 one-on-one weekly virtual sessions with a peer navigator and engage with components of the LinkPositively app (i.e., social networking, resource locator, medication monitoring, educational tips) for a 6-month period. View the enrollment flyer.
Enrollment: Now through 8/1/2023
Contact: Danielle M. Campbell, MPH; Email: dacampbe@health.ucsd.edu
Click here for more information and eligibility requirements
HIV
Summary: The purpose of this study is to evaluate the efficacy of a targeted therapy, loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy in persons with relapsed/refractory diffuse large B cell lymphoma.
Enrollment: Now through 2023
Contact: Erin Reid, MD at egreid@ucsd.edu
Click here for more information and eligibility requirements.
HIV CANCER
AMC-083: Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
Summary: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. This research trial is collecting tissue samples specifically from patients with HIV-related malignancies to study clinical, genetic, and immunologic parameters that have prognostic significance and/or are involved in the initiation and progression of HIV-1 malignancies, including complete genomic sequence determination of HIV-associated diffuse large B-cell lymphomas, lung cancer, anal cancer, and cervical cancer.
Enrollment: now through December 2024
Contact: Erin Reid, MD at egreid@ucsd.edu
Click here for more information and eligibility requirements.
HIV CANCER
This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response, who are planned to undergo stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.
Enrollment: now through December 2023.
Contact: Ayad Hamden, MD ayhamdan@health.ucsd.edu
Click here for more information and eligibility requirements.
HIV CANCER
This phase I-II trial studies the side effects and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas.
Enrollment: now through December 2024.
Contact: Erin Reid, MD egreid@ucsd.edu
Click here for more information and eligibility requirements
HIV CANCER
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated solid tumors have spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may block tumor growth in different ways by targeting certain cells. Ipilimumab is an antibody that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of your immune system by shutting it down. Nivolumab is a type of antibody that is specific for human programmed cell death 1 (PD-1), a protein that is responsible for destruction of immune cells. Giving ipilimumab with nivolumab may work better in treating patients with HIV associated solid tumors.
Enrollment: now through December 2023.
Contact: William Wachsman, MD/PhD, wwachsman@ucsd.edu
Click here for more information and eligibility requirements.
HIV CANCERAMC-096: sEphB4-HSA in Treating Patients With Kaposi Sarcoma
This phase II trial studies a targeted therapy, recombinant EphB4-HSA fusion protein(EphB4-HSA), in treating persons with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that comprise the cancer, and may also prevent cancer cells from growing.
Enrollment: now through December 2023.
Contact: Erin Reid, MD egreid@ucsd.edu
Click here for more information and eligibility requirements.
HIV CANCER